289: Batch-to-Batch Variability Is a Design Failure, Not the Norm with Sandra Núñez - Part 1

Batch-to-batch variability isn’t just a minor annoyance in bioprocess development; it’s often a systemic design flaw hiding in plain sight.

That’s the challenge Sandra Núñez, CEO of Amela Biosciences, set out to eliminate. Drawing on 15 years across Lonza, Medinova, Baxalta, and Biogen, she’s engineered a new generation of animal-free, recombinant protein matrices that promise researchers experimental consistency on demand.

Topics discussed:

• The widespread issue of batch-to-batch variability and why Sandra argues it’s a design failure, not the norm (02:49)
• The mechanics and biological tunability of Amela’s engineered protein matrices, and how this technology works (06:34)
• How Amela’s recombinant protein bioinks differ from traditional animal-sourced extracts, enabling reproducibility (08:53)
• Manufacturing insights: why the proteins are relatively straightforward to produce for research use (12:05)
• Engaging with users to optimize and customize protein matrices for diverse tissue and assay applications (13:33)
• The creation and use of protein libraries for specific user requirements and the flexibility this provides (16:20)
• Definitions and roles of ‘bioinks’ in tissue modeling and 3D cell culture (16:52)

Smart insight: Reproducibility remains the cornerstone of reliable science. With innovative platforms like Amela Biosciences’ engineered protein matrices, the future of tissue engineering and in vitro biology looks not just reliable, but radically empowering. If you’re striving for consistency, customizability, and cutting-edge technology in your workflows, the era of animal-free, batch-consistent bioinks has arrived.

Here are four episodes that pick up the same threads: animal-free matrices, reproducibility by design, and building a biotech without a factory:

• Episodes 271 - 272: From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture with Jan Hunik and Matt Baker
• Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito
• Episodes 275 - 276: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria Balet
• Episodes 279 - 280: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher Locher

Connect with Sandra Núñez:
Website: www.amelabiosciences.com
Company LinkedIn: www.linkedin.com/company/amela-biosciences-ag
Sandra’s LinkedIn: www.linkedin.com/in/sandra-nunez-ch
Sandra’s email: s.nunez@amelabiosciences.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show